XTX Topco Ltd Invests $804,000 in Hologic, Inc. (NASDAQ:HOLX)

Key Points

• XTX Topco Ltd invested approximately $804,000 in Hologic, Inc., acquiring 13,015 shares of the medical equipment provider's stock during the first quarter.
• Hologic's stock price increased to $67.91, with the company's market cap at $15.10 billion and a price-to-earnings ratio of 28.18.
• Analysts have mixed ratings on Hologic, with a consensus target price of $76.42, including recommendations of 11 holds, 6 buys, and 1 strong buy.

XTX Topco Ltd purchased a new stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,015 shares of the medical equipment provider's stock, valued at approximately $804,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. boosted its stake in Hologic by 34.4% in the first quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock worth $408,283,000 after buying an additional 1,692,177 shares in the last quarter. Invesco Ltd. boosted its stake in Hologic by 16.4% during the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after buying an additional 572,187 shares during the period. Northern Trust Corp boosted its stake in shares of Hologic by 26.9% during the fourth quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after buying an additional 668,086 shares during the period. Hsbc Holdings PLC boosted its position in shares of Hologic by 12.5% in the 4th quarter. Hsbc Holdings PLC now owns 2,770,281 shares of the medical equipment provider's stock worth $199,723,000 after buying an additional 307,109 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Hologic by 6.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,625,290 shares of the medical equipment provider's stock valued at $189,264,000 after purchasing an additional 169,427 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on HOLX. Citigroup upgraded Hologic from a "neutral" rating to a "buy" rating and raised their target price for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Raymond James Financial reiterated an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. Evercore ISI raised their target price on Hologic from $62.00 to $68.00 and gave the stock an "in-line" rating in a research report on Tuesday, July 8th. Finally, UBS Group upped their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, July 31st. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of "Moderate Buy" and a consensus price target of $77.83.

Hologic Trading Up 1.2%

Shares of NASDAQ HOLX traded up $0.81 during trading hours on Thursday, hitting $67.70. 610,951 shares of the company traded hands, compared to its average volume of 2,838,092. The company's 50 day moving average price is $64.87 and its 200 day moving average price is $62.77. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $15.06 billion, a price-to-earnings ratio of 28.11, a price-to-earnings-growth ratio of 2.46 and a beta of 0.49. Hologic, Inc. has a 12 month low of $51.90 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%. Hologic's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.06 earnings per share. On average, equities research analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.